지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Background : Chemotherapy-induced neutropenia can result in dose reductions and chemotherapy schedule delays, heightening the risk of complications and increasing infection rates, hospitalization, and mortality. The use of FOLFIRINOX in treating pancreatic cancer patients poses a significant risk of moderate-to-severe neutropenia, necessitating preventive granulocyte colony-stimulating factor (G-CSF) use. However, insufficient research in Korea on eflapegrastim’s secondary preventive effects warrants a comparative study. This research aimed to assess and compare the secondary preventive impacts of eflapegrastim and pegteograstim on neutropenia in patients with pancreatic cancer undergoing FOLFIRINOX/mFOLFIRINOX treatment.
Methods : A retrospective analysis was conducted on patients aged 19 and older who started FOLFIRINOX/mFOLFIRINOX treatment at a tertiary hospital from April 2021 to December 2022. Patients who received prophylactic eflapegrastim or pegteograstim for neutropenia were included. Electronic medical records were analyzed to compare the rates and occurrences of neutropenia between the two groups after the initiation of pegylated G-CSF.
Results : The study involved 47 participants in the eflapegrastim group and 174 in the pegteograstim group. The pegteograstim group exhibited a significantly higher median number of chemotherapy cycles (14 cycles) compared to the eflapegrastim group (12 cycles) (p = 0.04). After initiating pegylated G-CSF, the eflapegrastim group had a lower incidence of grade 3 and 4 neutropenia (37.8%) compared to the pegteograstim group (64.3%) (p < 0.01).
Conclusion : The study found significantly lower rates of grade 3 and 4 neutropenia in the eflapegrastim group than in the pegteograstim group. However, the retrospective nature and limited patient cohort of the study should be noted. The impact of differences in chemotherapy cycles between the two groups cannot be overlooked. Therefore, a larger prospective study is needed to confirm eflapegrastim’s secondary preventive effect on neutropenia.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Prevalence and Risk Factors Associated with Neutropenia in Hospitalized Patients with Systemic Lupus Erythematosus
대한류마티스학회지
2017 .01
-
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
비호지킨림프종 환자의 발열성 호중구감소증에 대한 페그필그라스팀의 예방효과
한국임상약학회지
2015 .01
-
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
Cancer Research and Treatment
2018 .01
-
Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
Gut and Liver
2021 .01
-
Exploring the intersection of laser technology and neutropenia: mechanisms, impacts, and mitigation strategies
MEDICAL LASERS
2024 .06
-
항암화학요법 환자의 호중구감소증 식이에 대한 지식과 이행
Asian Oncology Nursing
2018 .06
-
A phase 2 trial of neoadjuvant modified folfirinox chemotherapy for resectable pancreatic adenocarcinoma
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
The Role of Neoadjuvant FOLFIRINOX Treatment on Conversion Surgery in Locally Advanced Pancreatic Cancer
대한외과학회 학술대회 초록집
2021 .05
-
항암화학치료 후 발생한 호중구 감소증에 대한 사물탕가감방 증례 보고
동의생리병리학회지
2015 .02
-
항암화학치료 후 발생한 호중구 감소증에 대한 사물탕가감방 증례 보고
동의생리병리학회지
2015 .01
-
Survival improvement in locally advanced pancreatic cancer after FOLFIRINOX neoadjuvant treatment and conversion surgery
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Pancreaticoduodenectomy with combined hepatic artery and portal vein resection after laparoscopic division of pancreaticosplenic ligament due to FOLFIRINOX-induced hepatic toxicity related secondary hypersplenism
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .05
-
Pender의 건강증진 모형을 적용한 종양병동 간호사의 항암화학요법 관련 호중구감소증 관리지침 이행 영향요인
성인간호학회지
2019 .08
-
Incidence, Risk Factors, and Outcomes of Febrile Neutropenia in Thai Hematologic Malignancy Patients Receiving Chemotherapy: A 6-year Retrospective Cohort Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
Gut and Liver
2021 .01
-
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
Cancer Research and Treatment
2022 .10
-
Clinical impact of mitomycin-C induced neutropenia after hyperthermic intraperitoneal chemotherapy with cytoreductive surgery in colorectal cancer patients
대한외과학회 학술대회 초록집
2019 .10
-
Improvement of neutropenia in 2 adolescent cases treated with empagliflozin for glycogen storage disease type Ib
대한소아응급의학회지
2024 .07
최근 본 자료
댓글(0)
0